Insider Selling: Tempus AI (NASDAQ:TEM) CEO Sells 13,550 Shares of Stock

Tempus AI, Inc. (NASDAQ:TEM) CEO Ryan Fukushima sold 13,550 shares of Tempus AI stock in a transaction dated Tuesday, May 19th. The stock was sold at an average price of $44.07, for a total transaction of $597,148.50. Following the completion of the sale, the chief executive officer owned 603,558 shares of the company’s stock, valued at $26,598,801.06. This trade represents a 2.20% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Tempus AI Stock Performance

Tempus AI stock traded up $0.61 during midday trading on Thursday, hitting $46.49. The company’s stock had a trading volume of 3,802,434 shares, compared to its average volume of 5,629,236. Tempus AI, Inc. has a 1-year low of $41.73 and a 1-year high of $104.32. The company has a debt-to-equity ratio of 2.96, a current ratio of 3.31 and a quick ratio of 3.15. The company has a 50-day moving average price of $49.11 and a two-hundred day moving average price of $59.69. The company has a market cap of $8.35 billion, a price-to-earnings ratio of -27.03 and a beta of 3.99.

Tempus AI (NASDAQ:TEM) last issued its quarterly earnings data on Tuesday, May 5th. The company reported ($0.13) earnings per share for the quarter, topping the consensus estimate of ($0.21) by $0.08. The business had revenue of $348.12 million during the quarter, compared to analysts’ expectations of $345.44 million. Tempus AI had a negative net margin of 22.20% and a negative return on equity of 53.83%. The business’s revenue was up 36.1% on a year-over-year basis. During the same quarter in the previous year, the company earned ($0.24) EPS. As a group, sell-side analysts predict that Tempus AI, Inc. will post -1.35 earnings per share for the current year.

Institutional Trading of Tempus AI

Large investors have recently made changes to their positions in the company. Vanguard Group Inc. raised its holdings in shares of Tempus AI by 8.7% during the 4th quarter. Vanguard Group Inc. now owns 10,258,621 shares of the company’s stock worth $605,772,000 after buying an additional 817,014 shares in the last quarter. ARK Investment Management LLC raised its holdings in shares of Tempus AI by 5.3% during the 4th quarter. ARK Investment Management LLC now owns 7,557,583 shares of the company’s stock worth $446,275,000 after buying an additional 381,816 shares in the last quarter. GC Wealth Management RIA LLC acquired a new position in shares of Tempus AI during the 4th quarter worth $399,267,000. Sumitomo Mitsui Trust Group Inc. raised its holdings in shares of Tempus AI by 23.4% during the 1st quarter. Sumitomo Mitsui Trust Group Inc. now owns 4,326,313 shares of the company’s stock worth $195,636,000 after buying an additional 821,490 shares in the last quarter. Finally, Amova Asset Management Americas Inc. raised its holdings in shares of Tempus AI by 23.4% during the 1st quarter. Amova Asset Management Americas Inc. now owns 4,326,313 shares of the company’s stock worth $195,549,000 after buying an additional 821,490 shares in the last quarter. Institutional investors and hedge funds own 24.22% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently issued reports on the company. Wall Street Zen downgraded Tempus AI from a “hold” rating to a “sell” rating in a research report on Saturday, February 28th. Mizuho initiated coverage on Tempus AI in a research note on Thursday, February 19th. They issued an “outperform” rating and a $100.00 price target for the company. Guggenheim dropped their price target on Tempus AI from $95.00 to $60.00 and set a “buy” rating for the company in a research note on Monday, March 30th. Jefferies Financial Group initiated coverage on Tempus AI in a research note on Monday, April 13th. They issued an “underperform” rating and a $35.00 price target for the company. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Tempus AI in a research note on Thursday, January 22nd. Nine equities research analysts have rated the stock with a Buy rating, three have given a Hold rating and two have issued a Sell rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $68.64.

About Tempus AI

Tempus is a technology-driven healthcare company that applies artificial intelligence and machine learning to clinical and molecular data in order to advance precision medicine. Its primary focus lies in oncology, where the company offers comprehensive genomic profiling, digital pathology services and data-driven insights to inform personalized cancer care. By integrating DNA and RNA sequencing with structured clinical information, Tempus enables clinicians and researchers to identify targeted treatment options for patients based on the genetic characteristics of their tumors.

The company’s core offering centers on a scalable, cloud-based analytics platform that aggregates vast amounts of molecular and clinical data.